Advanced search
Publication Cover
Journal of Medical Economics Volume 13, 2010 - Issue 2
Submit an article Journal homepage
1,062
Views
32
CrossRef citations to date
0
Altmetric
Original Article

Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013

Alain Denis Yellow Window Management Consultants, Antwerp, Belgium
,
Lut Mergaert Yellow Window Management Consultants, Antwerp, Belgium
,
Christel Fostier Yellow Window Management Consultants, Antwerp, Belgium
,
Irina Cleemput Belgian Health Care Knowledge Centre, Brussels, Belgium
&
Steven Simoens Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, Leuven, BelgiumCorrespondence[email protected]
Pages 295-301 | Published online: 18 May 2010

Citations (32)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Margit Gombocz & Sabine Vogler. (2020) Public spending on orphan medicines: a review of the literature. Journal of Pharmaceutical Policy and Practice 13:1.
Read now
Daniel Resende Faleiros, Juliana Álvares, Alessandra Maciel Almeida, Vânia Eloisa de Araújo, Eli Iola Gurgel Andrade, Brian B. Godman, Francisco A. Acurcio & Augusto A. Guerra Júnior. (2016) Budget impact analysis of medicines: updated systematic review and implications. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 257-266.
Read now
Georgi Iskrov & Rumen Stefanov. (2014) Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. Orphan Drugs: Research and Reviews 4, pages 1-9.
Read now
Eline Picavet, David Cassiman & Steven Simoens. (2013) Do ultra-orphan medicinal products warrant ultra-high prices? A review. Orphan Drugs: Research and Reviews 3, pages 23-31.
Read now

Articles from other publishers (28)

Bettina M. Zimmermann, Johanna Eichinger & Matthias R. Baumgartner. (2021) A systematic review of moral reasons on orphan drug reimbursement. Orphanet Journal of Rare Diseases 16:1.
Crossref
Khadidja Abdallah, Isabelle Huys, Kathleen Claes & Steven Simoens. (2021) Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review. Frontiers in Pharmacology 12.
Crossref
Elenka Brenna, Barbara Polistena & Federico Spandonaro. (2020) The implementation of health technology assessment principles in public decisions concerning orphan drugs. European Journal of Clinical Pharmacology 76:6, pages 755-764.
Crossref
Se Hee Lee, Seung-Lai Yoo, Joon Seok Bang & Jong Hyuk Lee. (2020) Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007–2019). International Journal of Environmental Research and Public Health 17:9, pages 2991.
Crossref
Petra Maresova, Blanka Klimova & Kamil Kuca. (2018) Legislation, regulation and policies issues of orphan drugs in developed countries from 2010 to 2016. Journal of Applied Biomedicine 16:3, pages 175-179.
Crossref
Michael Schlander, Charalabos-Markos Dintsios & Afschin Gandjour. (2018) Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases. Value in Health 21:5, pages 525-531.
Crossref
Georgi Iskrov, Tsonka Miteva-Katrandzhieva & Rumen Stefanov. 2017. Rare Diseases Epidemiology: Update and Overview. Rare Diseases Epidemiology: Update and Overview 221 231 .
Tamás Zelei, Mária J. Molnár, Márta Szegedi & Zoltán Kaló. (2016) Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. Orphanet Journal of Rare Diseases 11:1.
Crossref
Victoria Divino, Mitch DeKoven, Michael Kleinrock, Rolin L. Wade, Tony Kim & Satyin Kaura. (2016) Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis. Orphanet Journal of Rare Diseases 11:1.
Crossref
Konstantins Logviss, Dainis Krievins & Santa Purvina. (2016) Impact of orphan drugs on Latvian budget. Orphanet Journal of Rare Diseases 11:1.
Crossref
Séverine HenrardFrancis Arickx. (2016) Negotiating prices of drugs for rare diseases. Bulletin of the World Health Organization 94:10, pages 779-781.
Crossref
Victoria DivinoMitch DeKovenMichael KleinrockRolin L. WadeSatyin Kaura. (2016) Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007–18. Health Affairs 35:9, pages 1588-1594.
Crossref
Monika Wagner, Hanane Khoury, Jacob Willet, Donna Rindress & Mireille Goetghebeur. (2015) Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation. PharmacoEconomics 34:3, pages 285-301.
Crossref
Mike Paulden, Tania Stafinski, Devidas Menon & Christopher McCabe. (2014) Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework. PharmacoEconomics 33:3, pages 255-269.
Crossref
Tim A Kanters, Adri Steenhoek & Leona Hakkaart. (2014) Orphan drugs expenditure in the Netherlands in the period 2006–2012. Orphanet Journal of Rare Diseases 9:1.
Crossref
Konstantins Logviss, Dainis Krievins & Santa Purvina. (2014) Rare diseases and orphan drugs: Latvian story. Orphanet Journal of Rare Diseases 9:1.
Crossref
Michael Schlander, Silvio Garattini, Søren Holm, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol de Solà Morales, Keith Tolley & Mondher Toumi. (2014) Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. Journal of Comparative Effectiveness Research 3:4, pages 399-422.
Crossref
Eline Picavet, Thomas Morel, David Cassiman & Steven Simoens. (2014) Shining a light in the black box of orphan drug pricing. Orphanet Journal of Rare Diseases 9:1, pages 62.
Crossref
Adam Hutchings, Carina Schey, Richard Dutton, Felix Achana & Karolina Antonov. (2014) Estimating the budget impact of orphan drugs in Sweden and France 2013–2020. Orphanet Journal of Rare Diseases 9:1, pages 22.
Crossref
K. Logviss, D. Krievins & S. Purvina. (2014) Trends in individual reimbursement of orphan drugs in Latvia in 2008–2011. SHS Web of Conferences 10, pages 00021.
Crossref
Arna S. Desser, Jan Abel Olsen & Sverre Grepperud. (2013) Eliciting Preferences for Prioritizing Treatment of Rare Diseases: the Role of Opportunity Costs and Framing Effects. PharmacoEconomics 31:11, pages 1051-1061.
Crossref
Sinéad M. Murphy, Araya Puwanant & Robert C. Griggs. (2012) Unintended effects of orphan product designation for rare neurological diseases. Annals of Neurology 72:4, pages 481-490.
Crossref
Eline Picavet, Marc Dooms, David Cassiman & Steven Simoens. (2012) Orphan Drugs for Rare Diseases: Grounds for Special Status. Drug Development Research 73:3, pages 115-119.
Crossref
Andrea Faeh. (2012) A Just Distribution of Health Care in the Case of Orphan Medicinal Products: Aligning the Interests of European Economic Integration and National Welfare Policy. European Journal of Social Security 14:1, pages 21-40.
Crossref
Wills Hughes-Wilson, Ana Palma, Ad Schuurman & Steven Simoens. (2012) Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?. Orphanet Journal of Rare Diseases 7:1, pages 74.
Crossref
Steven Simoens, David Cassiman, Eline Picavet & Marc Dooms. (2011) Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs. Drugs & Therapy Perspectives 27:10, pages 24-26.
Crossref
Eline Picavet, Marc Dooms, David Cassiman & Steven Simoens. (2011) Drugs for Rare Diseases: Influence of Orphan Designation Status on Price. Applied Health Economics and Health Policy 9:4, pages 275-279.
Crossref
Ciaran O’Neill. (2010) How can the risk that orphan drugs present to budgets be managed better?. Clinical Therapeutics 32:9, pages 1640-1641.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.